The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia： 1-year data

Aim： Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia. Methods： Postmenopausal women with primary osteoporosis or osteopenia were randomly assigned to the weekly group or daily group （n=145 for each） that received oral risedronate 35 mg once a week or 5 mg daily, respectively, for I year. The subjects＇ bone mineral densities （BMDs）, bone turnover markers （PINP and 15-CTX）, new vertebral fractures, and adverse events were assessed at baseline and during the treatments. Results： All subjects in the weekly group and 144 subjects in the daily group completed the study. The primary efficacy endpoint after I year, ie the mean percent changes in the lumbar spine BMD （95% CI） were 4.87% （3.92% to 5.81%） for the weekly group and 4.35% （3.31% to 5.39%） for the daily group. The incidences of clinical adverse events were 48.3% in the weekly group and 54.2% in the daily group. Conclusion; The weekly 35-mg and daily 5-mg risedronate dosing regimens during I year of follow-up show similar efficacy in improving BMDs and biochemical markers of bone turnover in Chinese postmenopausal women with osteoporosis or osteopenia. Moreover, the two dosing regimens exhibit similar safety and tolerability.